dofetilide vs dronedarone
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of dofetilide and dronedarone. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tikosyn
Multaq
Dofetilide (Tikosyn) helps keep your heart in a normal rhythm if you have atrial fibrillation or atrial flutter. It can also help convert these abnormal rhythms back to normal.
Multaq is a medicine that helps lower the risk of needing to stay in the hospital for atrial fibrillation (AFib). It is for people who have a history of AFib and are currently in normal heart rhythm.
This medicine is used to maintain a normal heart rhythm if you have atrial fibrillation or atrial flutter for more than a week, and your heart has been returned to a normal rhythm. It can also convert atrial fibrillation and atrial flutter to a normal rhythm. This medicine is for people who have bothersome symptoms from their atrial fibrillation or flutter.
Multaq is used to lower the risk of hospitalization if you have atrial fibrillation (AFib). AFib is an irregular heartbeat. This medicine is for people who used to have AFib, but are now in a normal heart rhythm.
Dofetilide belongs to a class of drugs called Class III antiarrhythmics. It works by changing the electrical activity in your heart. This helps to stabilize your heart rhythm and prevent irregular heartbeats.
Multaq is an antiarrhythmic drug. It works by changing the electrical signals in the heart. This helps to keep your heart in a normal rhythm and prevent AFib from returning.
- • Headache
- • Chest pain
- • Dizziness
- • Diarrhea
- • Nausea
- • Abdominal pain
- • Vomiting
- • Feeling weak or tired
- Atrial Fibrillation 1,058
- Dyspnoea 603
- Dizziness 552
- Fatigue 520
- Death 478
- Atrial Fibrillation 1,420
- Dyspnoea 838
- Fatigue 615
- Diarrhoea 477
- Nausea 472
This drug can cause life-threatening heart rhythm problems. To lower this risk, you must start or restart this medicine in a hospital where your heart can be watched closely for at least 3 days. The hospital staff will check your kidney function and heart rhythm regularly.
Multaq can increase the risk of death, stroke, and heart failure in patients with severe heart failure or permanent AFib. You should not take this medicine if you have severe heart failure that recently required hospitalization or if you have permanent AFib and will not be converted to a normal heart rhythm.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine will harm your unborn baby. Talk to your doctor about the risks and benefits of taking this medicine while pregnant or breastfeeding.
Multaq can harm an unborn baby. If you are a woman who could become pregnant, use effective birth control while taking Multaq. Do not breastfeed while taking Multaq and for 5 days after your last dose.
Also Compare, Nearby Drugs
Compare dofetilide with
Compare dronedarone with
How to Read This dofetilide vs dronedarone Comparison
dofetilide is classified in the Class III Antiarrhythmic drug class, while dronedarone sits within the Class III Antiarrhythmic class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, dofetilide has 3,211 submissions while dronedarone has 3,822. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for dofetilide or dronedarone.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.